5-Amino-1MQ
Typical Dosing Protocols (Research/Compounded Use Only) – 5-Amino-1MQ
Common protocol: 150–500 mcg subcutaneously once daily. Start at 150–250 mcg daily for the first 5–7 days, then titrate up to 300–500 mcg as tolerated.
Other reported ranges:
Beginner: 150–300 mcg once daily
Standard: 300–500 mcg once daily (or split 250 mcg twice daily)
Cycles: Typically 4–8 weeks on, followed by a 2–4 week break.
Reconstitution example (for a typical 10 mg vial): Add 2 mL bacteriostatic water (yielding ~5 mg/mL).
150 mcg = 0.03 mL (3 units on U-100 insulin syringe)
300 mcg = 0.06 mL (6 units)
500 mcg = 0.1 mL (10 units)
Administration: Subcutaneous injection (abdomen or thigh), preferably in the morning on an empty stomach. Some protocols also use oral capsules (50–100 mg daily), but subcutaneous is the primary research route for higher bioavailability.
Dosing is highly individualized based on goals and response—consult a qualified healthcare provider experienced with peptides for personalized guidance. This is for informational purposes only.
Key Potential Benefits of PE-22-28
Rapid Antidepressant-Like Effects and Mood Regulation
Provides fast-onset reductions in depressive behaviors in preclinical models, significantly decreasing immobility time in the forced swim test and latency to feed in novelty-suppressed feeding tests, often within days of treatment.
Enhances serotonergic neuron firing and emotional resilience by modulating TREK-1 channels, supporting improved mood balance, stress adaptation, and overall emotional well-being.
Demonstrates efficacy in models of depression, including post-stroke depression, with potential for quicker therapeutic response compared to traditional approaches in research settings.
Potent Stimulation of Hippocampal Neurogenesis
Induces rapid increases in new neuron formation (marked by elevated BrdU-positive cells) in the hippocampus after only 4 days of treatment, roughly doubling proliferation rates in mouse models.
Supports the birth, survival, and maturation of neurons in brain regions critical for mood and memory, helping counteract stress- or age-related declines in neurogenesis.
Contributes to long-term regenerative capacity in the brain through sustained neurotrophic signaling.
Enhanced Synaptogenesis and Synaptic Plasticity
Boosts expression of synaptic proteins such as PSD-95 and synapsin, leading to increased synapse formation, dendritic spine density, and stronger neural connections in cortical and hippocampal neurons.
Promotes maturation and integration of newborn neurons into existing circuits, improving synaptic strength and efficiency for better information processing.
Elevates BDNF (brain-derived neurotrophic factor) levels, reinforcing neuroplasticity and long-term potentiation essential for learning, memory, and emotional regulation.
Cognitive Enhancement and Memory Support
Improves memory consolidation, recall, focus, attention, mental clarity, and learning capacity through optimized hippocampal function and synaptic plasticity in preclinical models.
Supports executive function, processing speed, and overall cognitive efficiency, with potential benefits for counteracting cognitive deficits or maintaining performance under mental demands.
Aids in rescuing synaptic and dendritic impairments, fostering more robust neural networks for daily cognitive tasks.
Neuroprotective Effects and Support for Brain Resilience
Protects against neuronal damage from ischemia, oxidative stress, or other challenges, improving motor and cognitive outcomes in stroke models while preventing dopaminergic degeneration and weight loss.
Enhances brain adaptation to chronic stress or injury by reducing neuroinflammation markers and supporting neuronal survival pathways.
Shows promise for broader neuroprotective applications in models of neurodegenerative conditions and post-stroke recovery through modulated TREK-1 activity and plasticity.
Additional Advantages in Duration, Efficiency, and Broader Applications
Exhibits significantly prolonged duration of action (up to 23 hours in optimized analogs) compared to the parent Spadin compound, enabling more sustained modulation of TREK-1-related pathways.
Supports potential benefits in muscle function and tissue-level resilience in exploratory research, alongside its primary neurotrophic and mood-related effects.
Provides efficient blood-brain barrier penetration and high specificity for TREK-1 inhibition, positioning it as a multifaceted tool for studying rapid brain plasticity, mood stabilization, and cognitive optimization in preclinical settings.
